AAV AP-4 Gene Cassettes for AP-4-HSP Functional Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective disease-modifying treatments for AP-4-associated hereditary spastic paraplegia (AP-4-HSP), a rare genetic disorder characterized by spasticity, intellectual disability, and other severe symptoms, which is caused by loss-of-function mutations in the AP-4 adaptor protein complex, leading to impaired autophagosome formation and neuronal dysfunction.
Innovation Solution
Development of optimized expression vectors, such as AAV vectors, containing nucleic acid molecules encoding AP-4 complex subunits, operably linked with specific promoters and enhancers, to deliver and functionally replace dysfunctional AP-4 proteins in mammalian neurons, particularly motor neurons, thereby addressing the underlying genetic defect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used to deliver AP-4 complex subunit genes, then the ability to infect broad range of cells and avoid genomic integration is improved, but the payload capacity is limited by the small size of AAV genome
Solution Approach 1:
The AP-4 complex subunits are delivered as separate gene cassettes within the AAV vector, allowing modular packaging of multiple functional elements (promoters, coding sequences, polyadenylation signals) that collectively restore the defective protein complex while respecting vector size constraints
Solution Approach 2:
The patent optimizes the AAV vector by modifying genomic parameters including using compact promoter elements (CMV immediate early promoter), efficient polyadenylation signals (BGH polyA), and optimized intron placements to maximize the coding capacity within the limited AAV genome while maintaining high expression levels
2Reliability
If multiple AP-4 subunit genes are included in the expression cassette, then the functional replacement of dysfunctional AP-4 complex is improved, but the complexity of the expression construct increases
Solution Approach 1:
Multiple AP-4 subunit genes (AP4B1, AP4E1, AP4M1, AP4S1) are merged into a single AAV expression cassette with shared regulatory elements, allowing co-expression of all necessary subunits from one vector construct rather than requiring separate vectors for each gene
Solution Approach 2:
The AAV expression cassette is designed as a universal construct that can deliver multiple different AP-4 subunit combinations depending on the specific mutation type, making it applicable to various AP-4-HSP genetic variants through simple cassette modification
3Productivity
If optimized promoters and enhancers are used to enhance neuronal expression, then the expression level of AP-4 proteins is improved, but the risk of off-target effects and immune response increases
Solution Approach 1:
The patent employs the CMV immediate early promoter which, while potent, is combined with specific regulatory elements and intron placements that optimize expression specifically in neuronal contexts where AP-4 function is required, thereby enhancing local expression without excessive systemic activation
Solution Approach 2:
The use of introns within the expression cassette serves as an intermediary mechanism that enhances gene expression through proper splicing and mRNA processing while potentially reducing immunogenicity by modifying the expressed protein sequence without altering the amino acid sequence
Data Source
AI summary
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.